Medical devices, healthcare technology and the business of care
PMA approval · P250013

aura6000 system

LivaNova USA, Inc. · Decision date Mar 18, 2026

FDA DECISIONP250013

What did the FDA approve?

FDA records P250013 as an original PMA application. The recorded decision is approval, dated Mar 18, 2026.

FDA approval order statement

Approval for the aura6000 system, which includes the Implantable Pulse Generator Model #100.0100, Lead Models #300.0100 (25cm) and #300.0200 (33cm), Remote Control & Charger Model #500.0100, Charging Antenna Model #500.0300, aura Clinical Manager Model #700.0100, Torque Wrench, and Suture Sleeve. The device is indicated for the reduction of apneas, hypopneas, or both in adult patients with moderate to severe obstructive sleep apnea (OSA), defined as an apnea-hypopnea index (AHI) of = 15 and = 65. The aura6000 system is intended for patients who failed, do not tolerate, or are ineligible to be treated with current standard of care treatments such as positive airway pressure (PAP), oral appliances (e.g. mandibular advancement device), or pharmacotherapy. PAP failure is defined as an inability to eliminate OSA (AHI of greater than 15 despite PAP usage), and PAP intolerance is defined as: Inability to use PAP (greater than 5 nights per week of usage; usage defined as greater than 4 hours of use per night), or Unwillingness to use PAP (e.g., a patient returns the PAP system after attempting to use it).
Regulatory pathway
Original PMA
Clinical specialty
Anesthesiology
Decision date
Mar 18, 2026

FDA source record

Regulatory record facts

Identifier
P250013
Regulatory pathway
Premarket approval application
Product code
MNQ
Decision code
APPR
Decision date
Mar 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, hypoglossal nerve, implanted, apnea.

Product code
MNQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250013 received

    Application receipt date recorded by FDA.

  2. P250013 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250013

Product / regulatory recordCompanyPathwayDecision dateSource
aura6000 systemP250013/S001
LivaNova USA, Inc.PMA supplementApr 30, 2026FDA
aura6000 systemP250013/S002
LivaNova USA, Inc.PMA supplementJun 18, 2026FDA

Explore the linked device profile

Other records with product code MNQ

Product / regulatory recordCompanyPathwayDecision dateSource
Inspire Medical SystemsPMA supplementNov 5, 2026FDA
Inspire Medical SystemsPMA supplementOct 26, 2026FDA
Model 3150 IPGP130008/S147
Inspire Medical SystemsPMA supplementOct 22, 2026FDA
Model 3150 IPGP130008/S146
Inspire Medical SystemsPMA supplementOct 13, 2026FDA
Inspire Medical SystemsPMA supplementAug 28, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LivaNova USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
100 Cyberonics Blvd., Houston, TX, 77058

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records